23andMe Stock

23andme.com | Healthcare/Biotech | Founded: 2006 | Funding to Date: $791,607,056

23andMe was founded on April 1, 2006 by Anne Wojcicki and Linda Avery. The company offers consumer genetic testing as well as supports genetic research. The consumer genetics and research platform give customers interactive, web-based access to their genetic profile. They regularly increase the capabilities of the platform giving users more insight into their DNA. 23andMe was named by MIT Technology Review to its “50 Smartest Companies, 2017” List, and named one of Fast Company’s “25 Brands That Matter Now, 2017”. According to the company, 23andMe has millions of customers worldwide, and approximately 85% consented to participate in research. 23andMe is located in Mountain View, CA. As of December 2018.

ENTERPRISE VALUE (based on primary fundings)

Key Investors
Fidelity Investments
Casdin Capital
Altimeter Capital
Sequoia Capital

TEAM

Management Team
  • Anne Wojcicki - CEO & Co-Founder
  • Dean Schorno - CFO & Head of Operations
  • Kathy Hibbs JD - Chief Legal & Regulatory Officer
  • Richard Scheller Ph.D - Chief Scientific Officer & Head of Therapeutics
  • Mike Polcari - Vice President & Chief Architect
Board Members
  • Anne Wojcicki - 23andMe
  • Esther Dyson - Self
  • Nicholas Naclerio Ph.D - Illumina
  • Patrick Chung JD - Xfund
  • Neal Mohan - 23andMe
  • Roelof Botha - Sequoia Capital

NEWS

Washington Times

A woman researching her ancestry submitted her DNA to a genealogy website — and ended up leading police to her half brother, who left his DNA at a crime scene decades ago. The successes of DNA matching, however, are raising all sorts of legal and ethical questions about consent.

WSJ

Consumer genetics-testing company 23andMe’s sales growth was hit by privacy concerns last year, its chief executive said, at the same time touting the company’s drug development pipeline that she hopes will power its next phase.

Forbes

Why did the New York Times called genetic testing a "parlor trick"? They published an editorial this weekend warning that customers should be careful about 23andMe's genetic tests. I looked at my own 23andMe results to show that the Times got this wrong.

Token Index
Private Growth Index
To view this content, please sign up or login.

Sign Up  Log In

Close